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Abstract
Many viruses alter expression of proteins on the surface of infected cells including molecules important for immune
recognition, such as the major histocompatibility complex (MHC) class I and II molecules. Virus-induced downregulation of
surface proteins has been observed to occur by a variety of mechanisms including impaired transcription, blocks to
synthesis, and increased turnover. Viral infection or transient expression of the Ebola virus (EBOV) glycoprotein (GP) was
previously shown to result in loss of staining of various host cell surface proteins including MHC1 and b1 integrin; however,
the mechanism responsible for this effect has not been delineated. In the present study we demonstrate that EBOV GP does
not decrease surface levels of b1 integrin or MHC1, but rather impedes recognition by steric occlusion of these proteins on
the cell surface. Furthermore, steric occlusion also occurs for epitopes on the EBOV glycoprotein itself. The occluded
epitopes in host proteins and EBOV GP can be revealed by removal of the surface subunit of GP or by removal of surface N-
and O- linked glycans, resulting in increased surface staining by flow cytometry. Importantly, expression of EBOV GP impairs
CD8 T-cell recognition of MHC1 on antigen presenting cells. Glycan-mediated steric shielding of host cell surface proteins by
EBOV GP represents a novel mechanism for a virus to affect host cell function, thereby escaping immune detection.
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Introduction
EBOV is an enveloped, negative-stranded RNA virus, a
member of the family Filoviridae, and the causative agent of Ebola
viral hemorrhagic fever. To date, five subtypes of EBOV have
been identified: Zaire, Sudan, Co ˆte d’Ivoire, Reston and
Bundibugyo. EBOV Zaire is the most pathogenic subtype in
humans, with mortality rates reaching 90% [1]. The basis for the
high pathogenicity of EBOV is unclear, however immune
dysregulation has been hypothesized to play a role [2]. Similarly
to many other viral systems, EBOV infection appears to down-
modulate the expression of host surface proteins involved in
cellular recognition, most notably major histocompatibility
complex (MHC) molecules and integrins [3].
EBOV encodes two forms of its glycoprotein. One is a dimeric,
secreted form (sGP), which is transcribed directly from the viral
RNA [4,5] and whose function remains unclear. A second
glycoprotein species results from transcriptional editing of the
glycoprotein ORF and encodes a trimeric, membrane-bound form
(GP). This form is expressed at the cell surface and is incorporated
into the virion [4] and drives viral attachment and membrane
fusion. GP is initially translated as a precursor (GP0), which is then
cleaved by furin in the Golgi into two subunits, a surface subunit,
GP1 and a membrane-spanning subunit, GP2 [6]. These subunits
remain covalently connected through a single intermolecular
cysteine bond [7]. Expression of the main viral glycoprotein, GP,
has been shown to cause effects in cell culture on host surface
proteins similar to those observed during viral infection, and so is
proposed to be an important determinant of viral pathogenesis
[8,9,10,11]. Because sGP is the predominant form transcribed, it
has been postulated that the balance between sGP and GP serves
to regulate the cellular effects of GP [11].
Expression of high levels of EBOV GP in cultured cells disrupts
cell adhesion resulting in loss of cell-cell contacts as well as cell
rounding and loss of attachment to the culture substrate [8,10,12].
This can be observed in a variety of cell lines and primary cell
types [12]. Interestingly, while transient GP expression does not
cause death in human embryonic kidney 293T cells, primary
human cardiac microvascular endothelial cells have been reported
to undergo anoikis, or detachment-mediated apoptosis, upon
transduction of GP [12,13]. By flow cytometry, cells expressing GP
display dramatically lowered levels of various surface proteins,
including several members of the integrin family and MHC class I
(MHC1); however, the exact complement of surface proteins
affected by GP appears to differ by cell type [10,12,14].
Importantly, EBOV infection of 293T cells was observed to cause
PLoS Pathogens | www.plospathogens.org 1 September 2010 | Volume 6 | Issue 9 | e1001098similar reduction of b1 integrin and MHC1 staining by flow
cytometry, confirming that observations from transient GP
expression are not simply artifacts of overexpression [3]. The
effects of EBOV GP are caused by a highly glycosylated region in
GP1, the mucin domain [8,12,14]. This domain encompasses
approximately 150 amino acids, contains numerous N- and O-
linked glycosylation sites, and is a distinctive feature of filoviral
GPs. The mucin domain is not only necessary, but also sufficient
for the observed EBOV GP-mediated effects upon surface protein
expression and cellular adhesion [8,15].
Few studies have been undertaken to investigate the mechanism
by which EBOV GP disrupts adhesion and causes surface protein
downmodulation. Our recent analysis concluded that the cellular
endocytic factor dynamin does not play a role in surface protein
downmodulation, suggesting the process may not involve cycling
of proteins from the cell surface [15]. In contrast, Sullivan and
colleagues have reported that this process requires dynamin [14].
Additionally, it has been reported that the extracellular signal-
regulated kinases (ERK 1/2) play a role in downmodulation [16]
suggesting an active process. In the present study, we provide
direct evidence that EBOV GP-mediated loss of surface protein
recognition occurs via steric shielding of surface epitopes, not by
protein removal from the cell surface. Moreover, we demonstrate
that EBOV GP expression blocks MHC1-mediated stimulation of
T cells. Based upon these findings, we present a model in which
the heavily glycosylated EBOV glycoprotein acts as a ‘‘glycan
umbrella’’ to physically occlude access to host proteins, and GP
itself, thereby impairing host protein function. EBOV GP-
mediated steric occlusion represents a unique viral mechanism
to interfere with the function of host proteins.
Results
EBOV GP expression blocks surface protein staining
EBOV GP expression can dramatically reduce the observed
levels of numerous host cell surface proteins including factors
involved in immune recognition and cellular adhesion [10,12,14].
This effect can be seen by analysis of MHC1 or b1 integrin by flow
cytometry staining in HEK293T cells transiently expressing Zaire
EBOV GP (Figure 1A). Overall, a 10- to 50-fold reduction in
surface levels of these host markers is observed in cells transfected
with an EBOV GP cDNA. Additionally, there appears to be a
critical threshold of EBOV GP expression required to induce
surface protein downmodulation [15]. In parallel with the
decrease in staining for host proteins, EBOV GP expression also
appears to be reduced, resulting in a distinctive horseshoe-shaped
flow cytometry profile (Figure 1A and [14,15,16]). Despite this
apparent decrease in surface protein levels observed by flow
cytometry, there were no consistent, significant changes in total
protein levels for the EBOV glycoprotein upon analysis by
Western blot in either adherent or non-adherent EBOV GP
transfected cells (data not shown). To look directly at host protein
expression in cells expressing EBOV GP, nonadherent, GP-
Author Summary
The Ebola virus (EBOV) is a highly pathogenic virus that
infects humans and non-human primates, causing severe
disease or death in the majority of these cases. The
interaction of this virus with its host on a cellular level is
only just beginning to be understood. EBOV, like many
viruses, affects the expression or function of several cell
surface proteins, including adhesion factors and protein
complexes responsible for allowing the immune system to
recognize infected cells. Our group and others have
previously shown that expression of the main viral
glycoprotein of EBOV in cultured cells is sufficient to
cause this disruption. Here we have identified the
mechanism by which this disruption occurs. Heavily
glycosylated domains of the EBOV glycoprotein form a
steric shield over proteins at the cell surface. This steric
interference blocks the detection of affected surface
proteins using antibody reagents, but also has the
functional effect of abrogating cell adhesion and prevent-
ing interactions with CD8 T cells. The results from this
study highlight a novel mechanism for viral disruption of
host cell surface protein functions and give insight to
interactions between the Ebola virus and its host.
Figure 1. Transient expression of the EBOV glycoprotein
results in loss of surface staining of b1 integrin and MHC1.
(A) 293T cells were transfected with empty pCAGGS (vector) or vector
encoding GP. Floating and adherent cells were harvested 24 h after
transfection, pooled, and stained for GP using the KZ52 antibody,
followed by FITC-labeled secondary antibodies, and co-stained for b1
integrin or MHC1 with PE-Cy5 conjugated monoclonal antibodies and
assayed by flow cytometry. (B) Following transfection with vector
encoding GP, floating 293T cells were removed from adherent cells,
stained for b1 integrin and assayed by flow cytometry (left panel).
Similarly treated cells were mounted on coverslips, fixed, permeabilized
and stained for GP with mouse monoclonal antibodies, followed by
Alexa 594 conjugated antibodies and assayed by immunofluorescence
microscopy. A representative cell is shown (right panel).
doi:10.1371/journal.ppat.1001098.g001
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cytometry for expression of b1 integrin ([15] and Figure 1B, left
panel). As previously described [15], these nonadherent cells
represent the lower two quadrants of the ‘‘horseshoe’’ and appear
to have reduced levels of both b1 integrin and EBOV GP. In
contrast to the flow cytometry results, analysis of EBOV GP in
these cells by immunofluorescence microscopy after fixation and
permeabilization reveals extensive staining at the plasma mem-
brane (Figure 1B, right panel). Similar to these results, previously
published microscopic analysis of cells expressing EBOV GP also
shows extensive plasma membrane staining with little evidence of
significant accumulation of GP in internal vesicles [15,17].
To evaluate steady state levels of host proteins and EBOV GP in
cells transiently expressing the viral glycoprotein, the transfected
cells were fixed, permeabilized and analyzed by flow cytometry. In
vector-transfected cells, the permeabilization treatment had little
effect upon staining for b1 integrin or MHC1 (Figure 2A).
However, in cells transiently expressing EBOV GP, which
displayed dramatically reduced levels of b1 integrin and MHC1
by surface staining (Figure 2B, left column), fixation and
permeabilization reveals no decrease in either of these host
proteins (Figure 2B, right column). Similarly, the apparent loss of
EBOV GP staining is reversed by this treatment. These effects are
best illustrated by comparison of the lower two panels in Figure 2B
where without treatment, 9.3% of the cells displayed low MHC1
and EBOV GP levels, however after fixation and permeabilization
the number of double negative cells was reduced to background
levels and these now appear as MHC
+,G P
+ cells in the upper right
quadrant. As expected, the untransfected cell population of 32–
34% remains unaltered by this treatment (Figure 2B, upper left
quadrants). Overall, this analysis suggests that the apparent
downmodulation observed is not due to reduced steady-state
levels of protein. Rather these transfected cells express unaltered
levels of EBOV GP and MHC1, however these proteins are
inaccessible for surface staining.
EBOV GP shields its own epitopes at the cell surface
Recent structural analysis of EBOV GP suggests that the
recognition site for the monoclonal antibody, KZ52, employed in
the flow cytometry analysis resides near the base of the protein
[18] below the globular GP1 and heavily glycosylated mucin
domains in GP. This finding, coupled with our results suggesting
that downmodulation in these cells was not accompanied by a
reduction in steady-state levels of b1 integrin or MHC1, or a
significant re-localization of EBOV GP, prompted us to consider
the hypothesis that EBOV GP mediates its effects by blocking
access to epitopes of proteins on the cell surface including epitopes
within GP. Additionally, this hypothesis is consistent with the
apparent threshold of GP expression required for downmodula-
tion as well as the lack of a dynamin requirement [15].
To test this hypothesis, we engineered epitopes within EBOV
GP at locations which, based on their position relative to the
mucin domain and the globular region of GP, are predicted to be
more accessible than the KZ52 epitope. Two constructs were
created with an AU1 antibody epitope tag at the N or C terminus
of the mucin-like domain, termed NmucAU1 GP and CmucAU1
GP, respectively. Cartoon depictions of each construct are shown
in Figure 3C and D. These constructs were well expressed, as
judged by Western blot analysis for EBOV GP and the AU1 tag
(Figure 3A). The sub-cellular localization of these constructs was
also evaluated in HeLa cells by immunofluorescence microscopy
and was found to be indistinguishable from wt GP (Figure 3B).
Although the structure of the mucin domain is unknown, its
mucin-like O glycosylation may force the domain into an extended
conformation as has been suggested for cellular mucin proteins
[19]. This would likely position the C terminus of the mucin
domain so that it is more exposed compared to the GP core
(Figure 3C and D). Based upon the proposed steric occlusion
model, we hypothesized that the AU1 epitope of CmucAU1 would
be most accessible to antibody staining. In contrast, the AU1
epitope in NmucAU1 might be less accessible than the epitope in
CmucAU1 because of its location at the base of the mucin domain.
Cells expressing wt GP, CmucAU1 GP, and NmucAU1 GP were
analyzed by flow cytometry. When stained with the GP-specific
KZ52 antibody, the epitope-tagged mutants displayed the
characteristic comma-shaped flow cytometry plot seen with wt
GP (Figure 3C and D; top rows). In contrast to the reduced KZ52
staining observed, the AU1 epitope in CmucAU1 was highly
Figure 2. Steady-state levels of b1 integrin and MHC1 are
unchanged in GP-expressing cells. 293T cells were transfected with
empty vector (A) or vector encoding wt GP (B). Floating and adherent
cells were harvested 24 h after transfection, pooled, and stained for GP,
b1 integrin, and MHC1 as described earlier and assayed by flow
cytometry. Prior to staining, a portion of cells were fixed and
permeabilized to expose occluded surface and internal epitopes.
doi:10.1371/journal.ppat.1001098.g002
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panels). Staining of the AU1 epitope on NmucAU1 GP was
intermediate relative to CmucAU1 GP and wt GP KZ52 staining
(Figure 3C and D; bottom right panels). In support of the shielding
model, these data demonstrate that cells exhibiting reduced levels
of b1 integrin and MHC1 have high surface levels of GP as
Figure 3. The mucin and globular domains of the EBOV glycoprotein masks the KZ52 epitope on the cell surface. (A) 293T cells were
transfected with empty vector or vector encoding wt GP, CmucAU1 GP, or NmucAU1 GP. Lysates were harvested in RIPA buffer after 24 h and subjected to
SDS-4 to 15% PAGE, transferred to PVDF, and immunoblotted with anti-GP polyclonal rabbit antibodies (top blot) or anti-AU1 antibodies (bottom blot) and
anti-GAPDH antibodies. (B) HeLa cells were transfected with vector encoding wt GP, CmucAU1 GP, or NmucAU1 GP. 24 h after transfection, cells were fixed,
permeabilized, and stained for GP with mouse monoclonal antibodies, and the AU1 epitope with anti-AU1 antibodies, followed by Alexa 594 and Alexa 488
conjugated antibodies, respectively and assayed by immunofluorescence microscopy. Scale bars are 10.6 mm. (C, D) 293T cells were transfected with vector
encoding wt GP, CmucAU1 GP, or NmucAU1 GP. Floating and adherent cells were harvested 24 h after transfection, pooled, and stained for GP using the
KZ52 antibody or the AU1 tag, b1 integrin, and MHC1, as described earlier and assayed by flow cytometry. (C) b1 integrin vs. GP or AU1 surface staining. (D)
MHC1 vs. GP or AU1 surface staining. Cartoon depictions of the KZ52 epitope (red star), CmucAU1 epitope (green star) or NmucAU1 epitope (yellow star) are
shown below their respective flow cytometry plots. The globular region of GP is shown shaded blue; the mucin domain is shown shaded green.
doi:10.1371/journal.ppat.1001098.g003
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staining. Furthermore, these data suggest that antibody accessi-
bility to epitopes in GP differs based on the epitope position
relative to the mucin domain and the globular regions of GP1.
Removal of the EBOV GP1 subunit reveals shielded host
surface proteins
The data presented above are consistent with EBOV GP
affecting recognition of epitopes within GP by shielding, however
we wished to address if a similar mechanism was responsible for
the apparent downmodulation of host surface proteins. To directly
address whether EBOV GP sterically occludes host surface protein
epitopes, we sought to unmask MHC1 and b1 integrin staining.
We hypothesized that dissociation of the GP1 subunit, which
includes the mucin domain and globular ‘‘head’’ region of EBOV
GP, from GP2 at the cell surface should relieve the shielding of
previously occluded epitopes. The GP1 subunit is covalently linked
to GP2 via a single sulfahydryl bridge between residues C53 and
C609 [7]. We have previously demonstrated that this bond can be
reduced by incubation with DTT, allowing for dissociation of the
EBOV GP1 subunit from the surface of virions [20]. To confirm
that DTT is able to effectively remove GP1 from the cell surface,
cells expressing GP were incubated with DTT then the
supernatant was analyzed for GP by Western blot. Figure 4A
Figure 4. Removal of the GP1 subunit from the cell surface results in exposure of previously occluded surface epitopes. (A-C) 293T
cells were transfected with empty vector or vector encoding wt GP. Floating and adherent cells were harvested 24 h after transfection, pooled, and
either left untreated, or incubated at 37uC for 20 minutes in 150 mM DTT. (A) Western blot analysis of the GP1 subunit shed into the supernatant of
untreated or DTT-treated cells. (B) Cells were transfected with empty vector and assayed by flow cytometry to show baseline differences in surface
staining for b1 integrin and MHC1 between untreated cells (grey shading) and DTT-treated cells (black trace). (C) Cells were transfected with vector
encoding wt GP and assayed by flow cytometry for the internal proteins GM130 and calnexin to show the effect of DTT on cell permeabilization.
Untreated cells are shown in the grey shading; DTT-treated cells are shown in the black trace, and, as a positive control, fixed/permeabilized cells are
shown in the dashed trace. (D) Cells were transfected with vector encoding wt GP, were mock- or DTT-treated, stained for GP and b1 integrin or
MHC1 as described above, and assayed by flow cytometry. (E, F) 293T cells were transfected with empty vector or vector encoding wt GP or GP cl(-).
Cells were harvested and treated as above. (E) Western blot analysis using rabbit polyclonal antibodies of GP1 or GP0 shed into the supernatant of
untreated or DTT-treated cells. (F) Transfected and treated cells were surface stained for MHC1 and assayed by flow cytometry. Empty vector-
transfected, untreated cells are shown in the grey shading; GP-expressing cells are shown after mock treatment (black trace) or DTT treatment
(dashed trace).
doi:10.1371/journal.ppat.1001098.g004
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incubated with DTT compared to mock treated cells. Control
experiments also demonstrated that the DTT treatment did not
significantly alter surface expression of b1 integrin or MHC1 in
mock-transfected cells (Figure 4B). Moreover, this treatment did
not result in permeabilization of the cells (Figure 4C) which, as
shown above (Figure 2), could also rescue b1 integrin and MHC1
staining. In addition, these and the following experiments were
carried out in the presence of azide and 2-deoxy glucose to ensure
that the trafficking of nascent or recycled protein did not
complicate the interpretation of this assay.
We next examined the effect of DTT treatment on surface
staining of b1 integrin and MHC1 in cells expressing EBOV GP.
Flow cytometry analysis of the DTT-treated, GP-expressing cells
indicates that GP-induced loss of staining of b1 integrin and
MHC1 is reversed by DTT treatment and subsequent dissociation
of GP1 from the cells: upon DTT treatment, staining of b1 integrin
and MHC1 is restored to nearly control levels (Figure 4D).
Interestingly, staining for GP was also rescued, resulting in cells
that stained positively for both GP and b1 integrin or MHC1. This
is somewhat counter-intuitive, as KZ52 makes critical contacts
with residues on GP1 [18], which is removed from the cell surface
by DTT. These data suggest that DTT treatment removes a
significant amount of GP1 from the cell surface – enough to
reverse the steric occlusion of b1 integrin and MHC1 epitopes, as
well as the KZ52 epitope. However, sufficient GP1 remains on the
cell surface to allow for staining of GP by flow cytometry.
Supporting this hypothesis, there appears to be a very modest
downmodulation of integrin and MHC1 on the cells that appear
to have the highest levels of GP (Figure 4D, upper right quadrant
of the +DTT flow cytometry plots). This finding agrees with our
previously published study that suggests a threshold level of EBOV
GP is needed to downmodulate b1 integrin, MHC1 or GP [15].
Removal of surface GP1 by DTT reverses the apparent
downmodulation of surface proteins induced by EBOV GP. To
ensure this effect could be directly attributed to the EBOV
glycoprotein we tested the effect of DTT on cells expressing a
mutant form of GP lacking the endoproteolytic site required for
processing GP0 into GP1 and GP2 subunits. Previous analysis
demonstrated that this mutant EBOV glycoprotein, GP cl(-),
retains normal viral entry function [20,21] and is therefore likely
folded similarly to wt EBOV GP. As shown in Figure 4F, GP cl(-)
also downmodulates MHC1 similarly to wt EBOV GP. However
in contrast to wt GP, DTT treatment of cells expressing this
uncleaved form of GP does not relieve the observed down-
modulation of MHC1 (Figure 4F). As anticipated, DTT treatment
of cells expressing GP cl(-) produced no increase in GP release
compared to untreated cells (Figure 4E). The EBOV glycoprotein
found in the supernatant from the GP cl(-) expressing cells likely
represents trimeric GP released by the cellular enzyme TACE
[22]. Overall, these data strongly support the model proposed for
EBOV GP mediated occlusion of host surface proteins.
Carbohydrate modification of GP is important for steric
shielding
EBOV GP is a heavily glycosylated protein, and we have
previously shown the mucin domain to be sufficient to induce loss
of staining of host surface proteins by flow cytometry [15].
Therefore, we directly addressed whether GP glycosylation plays a
role in the shielding of surface epitopes. GP-expressing cells were
treated with several glycosidases or pre-treated with a small
molecule inhibitor of mucin synthesis, benzyl-a-GalNAc, then
assayed for b1 integrin staining by flow cytometry. Importantly,
none of the glycan-interfering treatments used here increased the
staining for b1 integrin in cells transfected with empty vector
(Figure 5A). Also, these treatments did not cause the permeabiliza-
tion of cells, allowing us to attribute changes in staining to
alterations at the cell surface (Figure 5B). Staining for b1 integrin
on GP-expressing cells was increased by incubation with
PNGaseF, an endoglycosidase that cleaves N-linked sugar moieties
(Figure 5D left). Similarly, staining for b1 integrin was increased
by incubation with neuraminidase, an exoglycosidase that cleaves
sialic acid, which is a common component of mucin sugars.
(Figure 5D, middle). When GP-expressing cells were incubated
with both PNGaseF and neuraminidase, an additive effect was
seen and b1 integrin staining was further increased (Figure 5D,
right). The effect of glycosidase treatment on cellular GP was also
analyzed by Western blot (Figure 5C, left). PNGaseF treatment
results in loss of the top band of GP1, which is the maturely-
glycosylated form and the appearance of bands which co-migrate
with GP1 that has been PNGaseF treated under denaturing
conditions, but which still contains O glycosylation. Treatment
with neuraminidase did not result in a perceivable shift in
migration of GP1; this is likely due to the small mass of these
glycans and the resolution of the gel. These data indicate a direct
role for N-linked glycans in GP-mediated loss of b1 integrin
staining.
To directly address the role of O glycosylation in host protein
downmodulation by EBOV GP, O glycosylation was perturbed by
pre-incubating cells with benzyl-a-GalNAc or the control vehicle
DMSO. This compound is a competitive inhibitor of b1,3-
galactosyltransferase, which prevents the modification of core O
glycan structures, resulting in shorter O-linked glycans and
reduced sialyation [23,24,25]. Cells pre-treated with benzyl-a-
GalNAc, then transfected with vector encoding GP showed
increased staining for b1 integrin compared to DMSO treated
cells, consistent with a role for O glycoslyation in the shielding of
epitopes by the GP mucin domain (Figure 5E, left plot). In cells
pre-treated with benzyl-a-GalNAc and expressing GP, incubation
with PNGaseF further increased staining for b1 integrin
(Figure 5E, right plot). Cells pre-treated with benzyl-a-GalNAc
were also incubated with O-glycosidase, which can cleave
unmodified core GalNAc structures; however, no further increase
in b1 integrin was observed (data not shown). This is perhaps due
to remaining modification of the core O glycans. The effect of
these treatments on GP glycosylation was analyzed by Western
blot (Figure 5C, right blot). Treatment with benzyl-a-GalNAc
results in a modest increase in mobility for bands corresponding to
GP containing O glycosylation, which are most easily seen in
samples that have been PNGase-treated after cell lysis. Our data
here suggest that the mass of O glycosylation is reduced, but not
fully eliminated. This is expected, as benzyl-a-GalNAc only
reduces mucin modification, but does not prevent the synthesis of
initial core glycans. Taken together, these data demonstrate that
surface N- and O- linked glycans, presumably on EBOV GP,
contribute to the ability of GP to mask surface b1 integrin
epitopes.
EBOV GP expression blocks MHC1 mediated T-cell
activation
The data presented above demonstrate that epitopes at different
locations within EBOV GP are differentially occluded in GP
expressing cells (Figure 3). To determine if a similar situation
occurs for cellular proteins, four monoclonal antibodies that
recognize distinct regions of MHC1 were analyzed. In cells
expressing GP, staining for MHC1 is blocked regardless of the
epitope examined (Supplemental Figure S1). Given the ability of
EBOV GP to effectively mask all of the epitopes examined on
Ebola GP Induced Steric Shielding
PLoS Pathogens | www.plospathogens.org 6 September 2010 | Volume 6 | Issue 9 | e1001098Figure 5. Surface N- and O- linked glycans contribute to GP-mediated shielding. (A, left plot) Cells transfected with empty vector were
mock incubated (grey shading) or incubated with neuraminidase and PNGaseF (black trace), stained for b1 integrin and assayed by flow cytometry.
(A, right plot) Cells were treated with DMSO, transfected with empty vector, and mock incubated (grey shading) or treated with benzyl-a-GalNAc (bz-
GalNAc), transfected with empty vector, and incubated with PNGaseF (black trace), then stained for b1 integrin and assayed by flow cytometry. (B)
Cells were left untreated and untransfected (grey shading), or treated with bzGalNAc, transfected with vector encoding GP, and incubated with
PNGaseF (black trace), then assayed by flow cytometry for the internal proteins GM130 and calnexin to show the effect of these treatments on cell
permeabilization. As a positive control, bz-GalNAc-treated, fixed/permeabilized cells are shown (dashed trace). (C, D) Floating cells in cultures
transfected with vector encoding GP were mock incubated or incubated with neuraminidase and/or PNGaseF, then analyzed by Western blot with
rabbit polyclonal antibodies to GP (C, left blot) or stained for b1 integrin and assayed by flow cytometry (D). (C, E) Cells were treated with DMSO or bz-
GalNAc, then transfected with empty vector, or vector encoding GP. Cells were then mock-incubated, or incubated with PNGaseF, then analyzed by
Ebola GP Induced Steric Shielding
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consequences for MHC1. Human OV79 cells expressing the
HIV Gag-derived peptide SLYNTVATL (SL9) were used to test
the effect of EBOV GP on MHC1 antigen presentation. These
cells present the SL9 antigen using a stably expressed MHC1,
HLA-A2. The OV79- SL9 cells were mock transduced or
transduced with adenoviral vectors encoding GFP (AdGFP) or
GFP and EBOV GP (AdGP), which resulted in nearly 100% of
cells expressing GFP (Figure 6A). Expression of EBOV GP
dramatically reduced MHC1 levels in these cells whereas the
control AdGFP vector had no effect on MHC1 expression
(Figure 6B). Primary human CD8 T-cells transduced with a
lentiviral vector expressing a T-cell receptor (868TCRwt) specific
for SL9 were used to assess antigen presentation by GP-expressing
OV79 cells. T-cell activation was measured by intracellular
staining for production of the cytokine MIP-1b in CD8
+
868TCRwt
+ expressing cells (Figure 6C). Production of MIP-1b
has been shown to be the most sensitive indicator of HIV-specific
CD8 T-cell activation [26]. Quantification of the CD8 activation
results demonstrates that expression of EBOV GP had a profound
effect on antigen presentation by the target cells, reducing T-cell
responses to nearly background levels (Figure 6D). In contrast, the
AdGFP control cells only modestly reduced the number of
responding T-cells. Similar results were obtained using 293T
target cells (data not shown). The ability of EBOV GP to interfere
with T-cell function does not appear to be caused by inhibitory
signaling from the GP-expressing antigen presenting cells (APCs)
since T-cells were fully activated when anti-CD3/CD28-coated
beads were added to a mixture of GP-expressing OV79 and CD8
+
868TCRwt
+ cells (data not shown). Given the observations that all
of the queried epitopes on MHC1 were occluded by GP
expression and that T-cells are not stimulated by these APCs,
the most straightforward explanation is that EBOV GP expression
impedes T-cell recognition of antigen presenting cells. Overall
these data support a model in which EBOV GP not only masks
MHC and other surface proteins from antibody recognition, it also
functionally inactivates them.
Discussion
An important component of the virus host interaction is viral
modulation of host functions. Many viruses alter expression
and/or function of host surface proteins to affect signaling,
immune surveillance, or viral superinfection. EBOV GP
expression in cell culture has been observed by several groups
to cause dramatic changes in cell adhesion and reduction in
surface protein staining by flow cytometry [10,12,14,16]. EBOV
infection causes a similar reduction of b1i n t e g r i na n dM H C 1
staining by flow cytometry, suggesting that observations from
transient GP expression are not simply artifacts of overexpres-
sion [3]. EBOV GP-induced effects have previously been
assumed to result from removal of surface proteins from the
plasma membrane. In this study we analyzed the mechanism of
downmodulation of host surface proteins by the Ebola viral
glycoprotein, GP. We show that reduction in surface staining for
the host proteins MHC1 and b1 integrin is not accompanied by
decreases in the total cellular levels of these proteins. Moreover,
the observed self downmodulation of EBOV GP does not result
in relocalization of GP away from the plasma membrane. Using
epitopes placed at various locations in EBOV GP we find that
the observed GP surface levels appear to differ based on epitope
position relative to the mucin domain and the globular regions
of EBOV GP. A similar observation has been made using a
series of monoclonal antibodies to EBOV GP [27]. Additionally,
the apparent downmodulation of surface proteins is reversed by
removal of the EBOV GP1 subunit by reduction or by
enzymatic digestion of the carbohydrate modification on EBOV
GP. Finally, our data demonstrate that EBOV GP expression
dramatically impairs antigen presentation by host cells. Taken
together these data support a model in which EBOV GP utilizes
a steric occlusion mechanism to downmodulate accessibility and
function of host surface proteins.
The ability of viruses to affect host surface proteins has been
well documented. For example, viruses may downregulate their
cellular receptor, as in the case of HIV downregulation of CD4
and measles virus downregulation of the complement regulatory
protein [28,29]. Other common targets for virus mediated
downmodulation are surface proteins related to immune surveil-
lance. MHC1 is known to be downregulated from the cell surface
by many viral proteins: HIV nef, Adenovirus E19, and KSHV K3
and K5, to name a few [30,31,32]. Activating ligands for natural
killer (NK) cells have also been shown to be actively downregu-
lated by KSHV and Hepatitis C virus [33,34]. Multiple
mechanisms and cellular pathways have been implicated in viral
dysregulation of the various host surface molecules (reviewed for
MHC1 in [35]). The model demonstrated here of glycan mediated
steric occlusion by EBOV GP represents, to our knowledge, a
distinctive mechanism for viral regulation of host surface proteins.
Indeed, a similar steric masking model has recently been proposed
for EBOV GP [27]. The polydnavirus, Microplitis demolitor
bracovirus expresses a mucin domain-containing glycoprotein
which can abrogate cell adhesion and thus may utilize a
mechanism similar to that proposed here for EBOV [36].
Our observation that enzymatic removal of carbohydrate
modification can relieve downmodulation, coupled with prior
observations that the mucin domain of EBOV GP is sufficient for
downregulation [8,15], suggests that the steric occlusion observed
is mediated, at least in part, by N- and O-linked modification of
EBOV GP. A similar glycan mediated steric hindrance model has
been proposed for cellular mucin proteins, which can disrupt a
variety of cell-cell interactions at the plasma membrane
[37,38,39,40,41]. For the cellular mucin proteins, densely-arrayed
O-linked glycans are critical for disruption of cell adhesion, with
different core glycan structure and subsequent modifications
influencing the function and anti-adhesive properties of the
protein [42]. Additionally, the number of mucin tandem repeats
positively correlates with the anti-adhesive properties of Muc1
[41]. Similarly, we have shown that sequential removal of
glycosylation sites in the mucin domain of EBOV GP led to a
step-wise reduction in cell detachment suggesting that such
modifications within GP are involved in downmodulation [12].
The O-linked glycosylation found on the EBOV GP mucin
domain may promote an extended conformation as is seen for
cellular mucin proteins [19] allowing this domain in GP to act as
an approximately 150 residue long flexible rod that can protrude
and mask epitopes in the immediate vicinity.
Western blot (C, right blot) or stained for b1 integrin and assayed by flow cytometry (E). For D and E, mock-incubated cells or DMSO-treated cells
transfected with empty vector= grey shading; GP-transfected and DMSO-treated or mock-incubated cells= black traces; GP-transfected and bz-
GalNAc- and glycosidase-treated cells= dashed traces. In Western blot panels (C), selected samples were lysed and denatured before incubation with
PNGaseF for comparison, as indicated.
doi:10.1371/journal.ppat.1001098.g005
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on the surface of a viral glycoprotein is well established.
Indeed, a glycan shield model has been proposed for other
viral glycoproteins, most notably HIV, as a mechanism to
avoid host immune recognition [43]. An extended glycosylated
protrusion provided by the mucin domain may be a
Figure 6. EBOV GP-induced disruption of MHC1 prevents activation of CD8
+ T cells. OV79 SL9 target cells were mock transduced (no Ad)
or transduced with Adenoviral vectors expressing GFP (Ad GFP) or GFP and EBOV GP (Ad GP) at an MOI of 300. 48 h after transduction, cells were
assayed for GFP expression (A); No Ad= blue trace; Ad GFP= green trace; Ad GP= orange trace. Cells were also stained for MHC1 (B); isotype
antibody= shaded peak; No Ad= blue trace; Ad GFP= green trace; Ad GP= orange trace. In parallel, CD8 T cells expressing a transgenic TCR
(868TCRwt) that recognizes the SL9 HLA-A2 complex were incubated alone or with mock- (no Ad) or Ad- transduced target cells in a 2:1 ratio. After
co-culture, T cells were surface stained for CD8, then fixed and permeabilized, and stained for 868TCRwt and MIP-1b with APC-H7, FITC, and PE-
conjugated antibodies, respectively, and assayed by flow cytometry. (C) CD8
+ and 868TCRwt
+ events were analyzed for MIP-1b staining. (D) Bar graph
depicts percent cells positive for MIP-1b, normalized to the No Ad target cell sample.
doi:10.1371/journal.ppat.1001098.g006
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of EBOV GP from other viral glycoproteins where the glycan
shield does not cause steric occlusion of host factors. Another
feature of the proposed model is that EBOV GP must localize
in close proximity to the affected proteins; perhaps within
plasma membrane microdomains inhabited by the host
proteins. This requirement may explain the critical threshold
for the observed GP effects as well as the variety of proteins
regulated by EBOV GP. It may be that the ability to occupy
these microdomains is, in addition to the extensive carbohy-
drate modification, a characteristic feature of EBOV GP.
Based upon our results it appears likely, therefore, that the
heavily glycosylated EBOV GP acts as a glycan umbrella to
physically occlude access to nearby host proteins, and GP
itself, thereby impairing host protein function.
It is intriguing to consider the role in EBOV replication or
pathogenesis of GP-induced steric occlusion of surface proteins.
Based upon our observations of proteins at the plasma membrane
it is plausible that EBOV GP functions to shield epitopes on the
surface of virions thereby contributing to infection and/or
persistence in the natural reservoir. Notably the KZ52 monoclonal
antibody employed in these studies is neutralizing but fails to
protect nonhuman primates from EBOV infection [44,45].
Perhaps variation in GP density on virions produced in vivo
differentially affects the neutralization sensitivity of viruses in
nonhuman primates. Additionally, the ability of GP to mask
MHC1 and other molecules on the cell surface, coupled with the
inhibitory effect of GP on cell-cell adhesion, may be a strategy for
avoiding CD8 T cell-mediated killing of EBOV infected cells. Our
data demonstrating that GP-expressing cells do not effectively
activate CD8 T cells supports this hypothesis. Interestingly, this
mechanism is proposed for adenocarcinomas, in which cellular
mucin protein overexpression can result in metastasis due to loss of
adhesion, and has been shown to prevent recognition and killing
by NK and cytotoxic T cells [38,46,47]. However, the rapid time
course of EBOV infection and its impairment of adaptive
responses may render escape from CD8 cells unnecessary in
humans. Instead, protection from NK cells may be more
important and the ability of EBOV GP to effect NK cell
recognition should be explored. Alternatively, the ability to mask
MHC1 may be more critical for viral infection or persistence in
the natural reservoir for EBOV. Finally, it is known that the
interface between the innate and adaptive immune response is
affected during EBOV infection (reviewed in [2]). We have
previously shown that EBOV GP causes rounding in macrophages
[12]. It is possible that EBOV GP shielding and inhibition of
adhesion molecules or other immune regulatory proteins on
professional antigen presenting cells such as macrophage or
dendritic cells plays a role in the immune dysfunction character-
istic of EBOV infection.
Materials and Methods
Plasmids and transfections
For GP studies, cDNA encoding the membrane-anchored form
of Zaire EBOV GP (Mayinga strain, accession number U23187)
was used. For AU1 tagged GPs, the amino acids, DTYRYI were
added using linker insertion into GP that had been engineered to
have a unique XhoI site at position 312 encoding the amino acids
LE (NmucAU1) and a unique NotI site replacing amino acid 463
with the amino acids KRPL (CmucAU1). EBOV GP harboring
mutations in the endoproteolytic site, GP cl(-), has been previously
described [20]. All constructs were cloned into the pCAGGS
expression vector.
293T and HeLa cells were cultured in DMEM (Gibco) with
10% fetal bovine serum (HyClone) and penicillin/streptomycin
(Gibco) at 37uC with 5% CO2. For flow cytometry and Western
blotting, 293T cells were plated in 10 cm or 6-well plates one day
prior to transfection. Cells were transiently transfected by
Lipofectamine 2000 according to manufacturer’s directions with
30 mgo r4 mg DNA per 10 cm plate or 6-well, respectively.
Immunofluorescence microscopy was performed using HeLa cells
that were plated on glass coverslips in 24-well plates and
transfected with 1.5 mg DNA as above.
Antigen-presenting and primary cells
Purified CD8 T cells from normal donors were obtained from
the University of Pennsylvania Center for AIDS Research
Immunology Core under a University of Pennsylvania IRB
approved protocol. The human ovarian adenocarcinoma line
OV79 has been described previously [48]. To create the OV79-
SL9 antigen-presentig cells, OV79 cells were sequentially
transduced to express HLA-A*02 [49] and a construct of GFP
fused to a codon-optimized sequence of HIV-1 p17 Gag50–102.
High titer lentiviral vectors were produced as described previously
[50].
Generation of SL9-specific CD8 T cells
Primary human CD8 T cells were cultured in X-Vivo 15
(Lonza) supplemented with 5% HABS (Valley Biomedical,
Winchester, VA), 2 mM GlutaMax and 25 mM HEPES (Invitro-
gen). CD8 T-cells were transduced to express the SL9-specific
HLA-A2 restricted 869TCR as described previously [51].
Transduction efficiencies were assessed by flow cytometric analysis
of TRBV5-6 staining (anti-Vbeta5a, Thermo-Fisher) or HLA-
A*02- SL9 tetramer stain (Beckman Coulter Immunomics).
Stimulation and analysis of SL9-specific CD8 T cells
OV79-SL9 cells were plated at 16,000 cells/well on 48 well
plates. After an overnight incubation cells were transduced with
adenovirus expressing GFP (Ad GFP) or GFP and the EBOV
Zaire glycoprotein (Ad GP) as described previously [12]. Briefly,
adenoviruses were diluted in media and applied to cells at an MOI
of 300. Media alone was used as a control. 48 h after transduction,
target cells were analyzed for GFP and HLA expression. Floating
and adherent cells, lifted by incubation with versene, were
combined and stained for HLA-ABC or isotype control with
APC-conjugated antibodies (BD-Biosciences). Alternatively, cells
were stained for different MHC1 epitopes with W6/32 (eBios-
ciences), YTH862.2 (Santa Cruz Biotechnology), BB7.2 (BD
Pharmingen), or GJ14 (Chemicon) primary antibodies, flowed by
Alexa Fluor 647 (Invitrogen) secondary antibodies. 10,000 viable
(forward scatter versus side scatter) events were collected on an
LSR-II flow cytometer running BD FACSDiva-6 (BD-Bioscienc-
es), and analyzed in FlowJo (Tree Star Inc.).
SL9-specific TCR–transduced CD8 T cells were mixed with
unmodified or adenovirally transduced OV79-SL9 target cells at a
2:1 ratio for 1 h, followed by 4 h in the presence of brefeldin-A
(Golgiplug, BD Biosciences). Stimulation with TPA (3 mg/ml,
Sigma-Aldrich) and ionomycin (1 mg/ml; Calbiochem) with
brefeldin-A was used as positive control. Cells were washed in
PBS and surface-stained using CD8 conjugated to APC-H7, and
then fixed and permeabilized with the Caltag Fix & Perm kit
(Invitrogen) and stained using anti-TRBV5-6 FITC and macro-
phage inflammatory protein-1b (MIP-1b, CCL4)-PE. Sequential
gates of 10,000 viable (forward scatter versus side scatter), CD8
positive events were acquired for all conditions on an LSR-II flow
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analyzed for cytokine production in FlowJo (Tree Star Inc.).
Cell lysates and Western blotting
Transfected cells were removed by resuspension in the culturing
media. Cells were pelleted at 4uC for 3 min at 13006g. Pellets
were resuspended in 1% Triton X-100 or RIPA buffer with
complete protease inhibitor cocktail (Roche) for 5 minutes. Lysates
were cleared by centrifugation at 4uC at 20,8006g. 30 ml samples
were mixed with reducing SDS buffer, boiled for 5 minutes, and
separated on a 4–15% Criterion PAGE gel (Bio-Rad). Proteins
were transferred to PVDF (Millipore) at a 400 mA constant
current. Membranes were blocked in 5% milk in TBS.
Membranes were probed with rabbit polyclonal anti-GP sera
which recognizes the GP1 subunit [52], rabbit anti-AU1 antibodies
(Bethyl labs), or anti-GAPDH monoclonal antibodies (Calbio-
chem) in blocking buffer. Protein was detected with stabilized goat
anti- rabbit or mouse HRP conjugated antibodies (Pierce) in
blocking buffer. Membranes were visualized with SuperSignal
Femto substrate (Pierce).
Flow cytometry
293T cells were detached from the plate 24 hours post
transfection with PBS lacking Ca
++ and Mg
++ (2/2), 0.5 mM
EDTA and combined with floating cells in culture media.
Alternatively, floating cells in cluture media were removed and
used exclusively (where indicated). Cells were pelleted at 4uCa t
2506g, then resuspended in flow wash buffer (PBS 2/2 with 1%
bovine calf serum and 0.05% NaAzide) and aliquoted for staining.
For detection of EBOV GP, cells were stained with the human
MAb, KZ52 [45] and detected with FITC anti-human IgG
(PharMingen). For detection of AU1 epitopes, cells were stained
with rabbit polyclonal anti-AU1 antibodies (Bethyl labs) and
detected with FITC goat anti-rabbit IgG (Rockland). For detection
of b1 integrin, cells were stained with anti-human CD29 PE-Cy5
conjugate (eBioscience); for detection of MHC1, cells were stained
with anti- HLA-ABC PE-Cy5 conjugate (eBioscience). For
intracellular staining, cells were permeabilized using Cytofix/
Cytoperm (BD Biosciences) for 20 min on ice, followed by washing
with Permwash (BD Biosciences). Antibodies where then diluted in
Permwash buffer. For detection of GM130 and calnexin, mouse
monoclonal FITC-conjugated antibodies were used (BD Trans-
duction Labs). All staining was performed on ice, followed by
washing. Live cell gates were drawn based on forward and side
scatter. For each sample, 10,000 or 20,000 events in the live cell
gate were collected and analyzed. Data were collected on a Becton
Dickinson FACSCalibur and analyzed using FlowJo software
(Tree Star, Inc.).
Immunofluorescence microscopy
For HeLa cells, media was removed at 24 hours post-
transfection, cells were washed with PBS and fixed with 3%
PFA in PBS for 20 minutes. For non-adherent 293T cells, media
containing floating cells was removed from plate, then centrifuged
onto poly-D-lysine coated coverslips (BD Biosciences), then fixed.
All samples were then washed with PBS, then permeabilized with
0.2% saponin, 1% goat serum in PBS for 5 minutes, then washed
with PBS. Cells were blocked with 10% goat serum, 0.1% Tween-
20 in PBS for 2 hours. For GP staining, coverslips were incubated
with mouse anti-EBOV GP MAb 42/3.7 (gift from Yoshihiro
Kawaoka) and detected with goat anti-rabbit Alexa Fluor 594
antibodies (Invitrogen). For AU1 staining, coverslips were
incubated with rabbit anti-AU1 antibodies (Bethyl labs) and
detected with anti-rabbit Alexa Fluor 488 antibodies (Invitrogen).
Cells were washed with PBS after each staining step. Coverslips
were mounted on glass slides with mounting medium containing
DAPI (Vectasheild). Z-section images were collected on a Leica
DMRE fluorescence microscope using Open Lab software
(Improvision). Thirty z-sections per image were collected at
0.2 mm intervals. Z-section data were deconvoluted using Velocity
software (Improvision) to a 98% confidence level or 15 iterations.
Images shown are single, deconvoluted, z-sections.
DTT treatment
At 24 hours post-transfection, sodium azide was added to
0.1% and 2-deoxy glucose was added to 10 mM. Cells were
incubated an additional 30 min. Cells were then harvested and
resuspended in flow wash buffer supplemented with 0.1% azide
and 10 mM 2-deoxy glucose. DTT was then added to 150 mM
a n dc e l l sw e r ei n c u b a t e da t3 7 uC for 20 minutes. Cells were
then pelleted at room temperature and the supernatant was
r e m o v e da n db l o t t e df o rG Pa sd e s c r i b e da b o v e .C e l l sw e r et h e n
washed twice in flow wash and stained for flow cytometry as
described above.
Glycosidase treatment
At 24 hours post-transfection, floating cells were harvested and
resuspended in 100 ml flow wash buffer. 100 U of neuraminidase
(NEB) and/or 1000 U of PNGaseF (NEB) was then added. Cells
were then incubated at 37uC for 20 minutes. Cells were then
washed twice and aliquoted for flow cytometry or Western
blotting as described above. Alternatively, cells were incubated
with 2 mM benzyl-a-GalNAc (Sigma) or DMSO at 31uCf o r
48 hours. Cells were then given fresh media with 2 mM benzyl-
a-GalNAc or DMSO and cultured at 37uC for 1 hour. Cells were
then transfected as described above. At 24 hours post-transfec-
tion, floating and adherent cells were harvested and resuspended
in 100 ml flow wash buffer. 1000 U of PNGaseF (NEB) or
2.5 mU of O-glycosidase (Sigma) was then added. Cells were
then incubated and analyzed as above. For PNGaseF treatment
of cell lysates, 30 ml of lysate was incubated with glycoprotein
denaturing buffer (NEB) for 10 minutes at 60uC. Samples were
then incubated with G7 buffer, NP40, and 500 U PNGase F
(NEB) for 2 hours at 37uC, then blotted for GP as described
above.
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Supporting Information
Figure S1 EBOV GP masks multiple epitopes on MHC1. OV79
SL9 target cells were mock transduced or transduced with
Adenoviral vectors expressing GFP (Ad GFP) or GFP and EBOV
GP (Ad GP) at an MOI of 300. 48 h after transduction, cells were
indirectly stained for different epitopes on MHC1 with primary
antibody clones W6/32, YTH862.2, BB7.2 and GJ14 and
detected with Alexa Fluor 647-conjugated secondary antibodies;
isotype antibody= grey peak; mock transduction= blue trace; Ad
GFP= green trace; Ad GP= orange trace. The approximate
location of each epitope is marked by the yellow star in a cartoon
depiction of MHC1 to the right of each graph. The W6/32 clone
recognizes the MHC1 heavy chain and the b2 microglobulin. The
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a2 domain of the heavy chain. The GJ14 clone recognizes the b2
microglobulin.
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